Therapeutics Company Reports Positive Results For Cancer Therapy

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort.

All information provided in this article is accurate, factual, and up-to-date.

Indaptus Therapeutics Inc. (NASDAQ: INDP), a pioneering biopharmaceutical company, has recently announced encouraging results from the second cohort of its Phase 1 clinical trial. This announcement marks a significant milestone in the company's relentless efforts to develop gr…